Drug Profile
Research programme: apolipoprotein A-I stimulants - VIRxSYS
Alternative Names: Lipid disorders gene therapy - VIRxSYS; Research programme - dyslipidemia gene therapy - VIRxSYS; SMaRT ApoA1; VRX1243Latest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator Intronn
- Developer VIRxSYS Corporation
- Class Gene therapies
- Mechanism of Action Apolipoprotein A I stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Dyslipidaemias
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Dyslipidaemias in USA (Parenteral)
- 17 Feb 2011 Preclinical development is ongoing in USA
- 17 Jan 2008 VIRxSYS establishes CRADA with the National Heart, Lung, and Blood Institute (NHLBI) for the development of therapeutics in Atherosclerosis